Details
Stereochemistry | ACHIRAL |
Molecular Formula | C36H42N2.2Br |
Molecular Weight | 662.54 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].[Br-].C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C3=C1C=CC=C3)C4C5=C(C=CC=C5)C6=C4C=CC=C6
InChI
InChIKey=WDEFPRUEZRUYNW-UHFFFAOYSA-L
InChI=1S/C36H42N2.2BrH/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36;;/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3;2*1H/q+2;;/p-2
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C36H42N2 |
Molecular Weight | 502.7321 |
Charge | 2 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/948350
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/948350
Hexafluorenium inhibits the enzyme cholinesterase in the plasms, but apparently not at the neuromuscular juntion. It also has some nondepolarizing activity (tubocurarine-like) at the postjunctional membrane. In man hexafluorenium potentiates the muscle relaxant effects of succinylcholine. As such, smaller doses of succinylcholine are required and fewer side effects like fasciculations, twitching and postoperative muscle pain are experienced.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01636a037 | http://www.google.ru/patents/US2783237
Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/hexafluorenium-bromide.html | https://www.ncbi.nlm.nih.gov/pubmed/5354795
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P06276 Gene ID: 590.0 Gene Symbol: BCHE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/948350 |
2.4 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | MYLAXEN Approved UseUsed as an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=009789 https://books.google.ru/books?id=cQkrDAAAQBAJ&pg=PA224&lpg=PA224&dq=HEXAFLUORENIUM+dosage&source=bl&ots=emH5xIW6_Z&sig=rxIXxG4jzMSsjPyY6oRmuvpf0IQ&hl=ru&sa=X&ved=0ahUKEwjI8_qpnKvUAhVCrRQKHWLPBZsQ6AEIOjAD#v=onepage&q=HEXAFLUORENIUM&f=false
Hexafluorenium has been employed in a dose of 0.4 mg/kg i.v. to prolong the relaxant effects of succinylcholine
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:09:06 GMT 2023
by
admin
on
Fri Dec 15 15:09:06 GMT 2023
|
Record UNII |
B64NJG83K2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29698
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
||
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
HEXAFLURONIUM BROMIDE
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
DTXSID6048753
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
53017
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | RxNorm | ||
|
1143
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
9434
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
19477
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
C65847
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
100000083974
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
SUB08027MIG
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
317-52-2
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201349
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
m5990
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00941
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
206-265-0
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY | |||
|
B64NJG83K2
Created by
admin on Fri Dec 15 15:09:06 GMT 2023 , Edited by admin on Fri Dec 15 15:09:06 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |